Mission & Vision
Our company's mission is to enhance the safe and optimal use of human proteins.
Octapharma respects donated human plasma as a scarce and valuable resource. We meet our mission through the use of cutting-edge, validated viral inactivation and state-of-the-art purification technologies, in order to achieve the highest production yields and manufacture medical products with the highest possible safety margins.
Octapharma has implemented a strategy of continuous investment in, and enhancement of both existing products as well as new products to develop a world-class portfolio of human proteins for the future.
In addition to our plasma-based activities, Octapharma has dedicated increasing resources over the past decade to human recombinant protein Research & Development (R&D). This involves the use of cultured human cells to produce therapeutic protein products in specific therapy areas such as hemophilia.
Our vision is to continuously improve treatment for the benefit of all patients with life-threatening diseases, by engaging top researchers in R&D, regularly contributing new clinical information, and establishing solid relationships with patient-centered organizations.
Octapharma was founded in 1983 on the fundamental principle of improving the lives of patients. Since then, we have remained focused on our collective responsibility for the trust instilled in us by physicians and patients worldwide. In 2012, the Octapharma Board identified the core strategic pillars, which will lead to the achievement of the organization’s ambitious long-term goals.
"The foundation of our identity is our patient-oriented corporate culture. We aim to increase our product portfolio to access the global market; to enter the recombinant business successfully; to increase plasma availability and throughput; to nurture a healthy organization with proud and talented employees and to continue to have open and transparent communication. These strategic pillars, we believe, will lead to further successes and profitable organic growth. These core elements define our future resource investments and continue to focus our internal and external activities."
Wolfgang Marguerre, Chairman of Octapharma Group